Victrex Given Underperform Rating at Bank of America Corp. (VCT)
Victrex (LON:VCT)‘s stock had its “underperform” rating reaffirmed by equities research analysts at Bank of America Corp. in a research note issued to investors on Wednesday, AnalystRatingsNetwork.com reports. They currently have a GBX 1,400 ($22.46) target price on the stock. Bank of America Corp.’s price objective indicates a potential downside of 10.26% from the company’s current price.
A number of other analysts have also recently weighed in on VCT. Analysts at Nplus1 Brewin reiterated a “hold” rating on shares of Victrex in a research note to investors on Tuesday. They now have a GBX 1,645 ($26.39) price target on the stock. Separately, analysts at N+1 Singer reiterated a “hold” rating on shares of Victrex in a research note to investors on Tuesday. They now have a GBX 1,645 ($26.39) price target on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of Victrex in a research note to investors on Tuesday. They now have a GBX 1,760 ($28.24) price target on the stock. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of GBX 1,661.54 ($26.66).
Shares of Victrex (LON:VCT) traded up 0.71% on Wednesday, hitting GBX 1560.00. The stock had a trading volume of 165,737 shares. Victrex has a 1-year low of GBX 1366.00 and a 1-year high of GBX 1791.00. The stock has a 50-day moving average of GBX 1593. and a 200-day moving average of GBX 1609.. The company’s market cap is £1.313 billion.
Victrex plc is engaged in the manufacturing and selling of high performance polymers. The Company’s business is organized as two business units: Victrex Polymer Solutions (LON:VCT) and Invibio Biomaterial Solutions (Invibio).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.